These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 27545845)

  • 41. Usefulness of Frequency Domain Optical Coherence Tomography Compared with Intravascular Ultrasound as a Guidance for Percutaneous Coronary Intervention.
    Kim IC; Yoon HJ; Shin ES; Kim MS; Park J; Cho YK; Park HS; Kim H; Nam CW; Han SW; Kim YN; Kim KB; Hur SH
    J Interv Cardiol; 2016 Apr; 29(2):216-24. PubMed ID: 26927366
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low major adverse cardiac event rates following bioresorbable vascular scaffold implantation: Impact of implantation technique on treatment outcomes.
    Ganeshkumar AV; Patil RS; Hamid IK
    Indian Heart J; 2018; 70(1):10-14. PubMed ID: 29455763
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: Clinical outcomes from randomized controlled trials.
    Rizik DG; Hermiller JB; Kereiakes DJ
    Catheter Cardiovasc Interv; 2016 Nov; 88(S1):21-30. PubMed ID: 27797464
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Spontaneous coronary artery dissection treated with biovascular scaffolds guided by intravascular ultrasounds imaging.
    Cerrato E; Tomassini F; Rolfo C; Gagnor A; Varbella F
    Cardiovasc Interv Ther; 2017 Apr; 32(2):186-189. PubMed ID: 27023796
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and efficacy of everolimus-eluting bioresorbable vascular scaffold for cardiac allograft vasculopathy (CART).
    Pighi M; Tomai F; Fezzi S; Pesarini G; Petrolini A; Spedicato L; Tarantini G; Ferlini M; Calabrò P; Loi B; Ferrero V; Forero MNT; Daemen J; Ribichini F
    Clin Res Cardiol; 2024 Jul; 113(7):1017-1029. PubMed ID: 38170246
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry.
    Hoppmann P; Kufner S; Cassese S; Wiebe J; Schneider S; Pinieck S; Scheler L; Bernlochner I; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
    Catheter Cardiovasc Interv; 2016 Apr; 87(5):822-9. PubMed ID: 26708019
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bioresorbable vascular scaffolds in left main coronary artery disease.
    Everaert B; Capranzano P; Tamburino C; Seth A; van Geuns RJ
    EuroIntervention; 2015; 11 Suppl V():V135-8. PubMed ID: 25983148
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Determinants of slow flow following stent implantation in intravascular ultrasound-guided primary percutaneous coronary intervention.
    Watanabe Y; Sakakura K; Taniguchi Y; Yamamoto K; Wada H; Fujita H; Momomura SI
    Heart Vessels; 2018 Mar; 33(3):226-238. PubMed ID: 28887713
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stent Expansion Indexes to Predict Clinical Outcomes: An IVUS Substudy From ADAPT-DES.
    Fujimura T; Matsumura M; Witzenbichler B; Metzger DC; Rinaldi MJ; Duffy PL; Weisz G; Stuckey TD; Ali ZA; Zhou Z; Mintz GS; Stone GW; Maehara A
    JACC Cardiovasc Interv; 2021 Aug; 14(15):1639-1650. PubMed ID: 34353595
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of the Use of Intravascular Imaging on Patients Who Underwent Orbital Atherectomy.
    Lee MS; Shlofmitz E; Kong J; Lluri G; Srivastava PK; Shlofmitz R
    J Invasive Cardiol; 2018 Feb; 30(2):77-80. PubMed ID: 29378972
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population.
    Costopoulos C; Latib A; Naganuma T; Miyazaki T; Sato K; Figini F; Sticchi A; Carlino M; Chieffo A; Montorfano M; Colombo A
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):E10-5. PubMed ID: 24909303
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neointimal tissue component assessed by tissue characterization with 40 MHz intravascular ultrasound imaging: comparison of drug-eluting stents and bare-metal stents.
    Tsujita K; Takaoka N; Kaikita K; Hokimoto S; Horio E; Sato K; Mizobe M; Nakayama N; Kojima S; Tayama S; Sugiyama S; Nakamura S; Ogawa H
    Catheter Cardiovasc Interv; 2013 Dec; 82(7):1068-74. PubMed ID: 23460385
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A true bifurcational stenosis treated with a bioresorbable vascular scaffold and a drug-eluting metallic stent: Degradable meets durable.
    Wiebe J; Hamm C; Nef H
    Catheter Cardiovasc Interv; 2015 Jun; 85(7):1184-8. PubMed ID: 25581885
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A new novolimus-eluting bioresorbable scaffold for large coronary arteries: an OCT study of acute mechanical performance.
    Boeder NF; Koepp T; Dörr O; Bauer T; Mattesini A; Elsässer A; Möllmann H; Blachutzik F; Achenbach S; Ghanem A; Hamm CW; Nef HM
    Int J Cardiol; 2016 Oct; 220():706-10. PubMed ID: 27393853
    [TBL] [Abstract][Full Text] [Related]  

  • 55. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Paving the way to a bioresorbable technology: Development of the absorb BRS program.
    Perkins LE; Kossuth MB; Fox JC; Rapoza RJ
    Catheter Cardiovasc Interv; 2016 Nov; 88(S1):1-9. PubMed ID: 27797462
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
    Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: the assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study.
    Witzenbichler B; Maehara A; Weisz G; Neumann FJ; Rinaldi MJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Brodie BR; Stuckey TD; Mazzaferri EL; Xu K; Parise H; Mehran R; Mintz GS; Stone GW
    Circulation; 2014 Jan; 129(4):463-70. PubMed ID: 24281330
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serial in vivo intravascular ultrasound-based echogenicity changes of everolimus-eluting bioresorbable vascular scaffold during the first 12 months after implantation insights from the ABSORB B trial.
    Brugaletta S; Gomez-Lara J; Serruys PW; Farooq V; van Geuns RJ; Thuesen L; Dudek D; Koolen J; Chevalier B; McClean D; Windecker S; Smits PC; de Bruyne B; Whitbourn R; Meredith I; van Domburg RT; Sihan K; de Winter S; Veldhof S; Miquel-Hebert K; Rapoza R; Garcia-Garcia HM; Ormiston JA; Bruining N
    JACC Cardiovasc Interv; 2011 Dec; 4(12):1281-9. PubMed ID: 22192369
    [TBL] [Abstract][Full Text] [Related]  

  • 60. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.
    Ormiston JA; Serruys PW; Onuma Y; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Garcia-Garcia HM
    Circ Cardiovasc Interv; 2012 Oct; 5(5):620-32. PubMed ID: 23048057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.